The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) hit a new 52-week low and has $5.41 target or 12.00% below today’s $6.15 share price. The 9 months bearish chart indicates high risk for the $182.20 million company. The 1-year low was reported on Oct, 28 by Barchart.com. If the $5.41 price target is reached, the company will be worth $21.86M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 53,579 shares traded hands. Tandem Diabetes Care Inc (NASDAQ:TNDM) has declined 24.91% since March 28, 2016 and is downtrending. It has underperformed by 29.62% the S&P500.
Analysts await Tandem Diabetes Care Inc (NASDAQ:TNDM) to report earnings on November, 3. They expect $-0.58 EPS, up 10.77% or $0.07 from last year’s $-0.65 per share. After $-0.60 actual EPS reported by Tandem Diabetes Care Inc for the previous quarter, Wall Street now forecasts -3.33% EPS growth.
Tandem Diabetes Care Inc (NASDAQ:TNDM) Ratings Coverage
Out of 2 analysts covering Tandem Diabetes Care (NASDAQ:TNDM), 0 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 0 are positive. Tandem Diabetes Care has been the topic of 10 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The company was downgraded on Thursday, January 14 by Bank of America. The company was downgraded on Friday, August 28 by Zacks. The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) has “Hold” rating given on Friday, September 4 by Zacks. Zacks downgraded the stock to “Buy” rating in Thursday, August 20 report. The firm has “Buy” rating given on Monday, August 10 by Deutsche Bank. Zacks upgraded the shares of TNDM in a report on Saturday, August 22 to “Hold” rating. The rating was downgraded by Bank of America on Thursday, March 24 to “Underperform”. The stock of Tandem Diabetes Care Inc (NASDAQ:TNDM) has “Sell” rating given on Wednesday, August 5 by Zacks.
According to Zacks Investment Research, “Tandem Diabetes Care, Inc. is a medical device company. The Company designs, develops, and commercializes products for people with insulin-dependent diabetes. Its products include t:slim Insulin Delivery System. Tandem Diabetes Care, Inc. is headquartered in San Diego, California.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.26, from 1.28 in 2016Q1. The ratio is negative, as 18 funds sold all Tandem Diabetes Care Inc shares owned while 24 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 17.85 million shares or 6.33% less from 19.06 million shares in 2016Q1.
Blackrock Invest Lc has 67,977 shares for 0% of their US portfolio. Senzar Asset Mngmt Lc has 0% invested in the company for 615,311 shares. Franklin Resources Inc accumulated 1.26 million shares or 0.01% of the stock. Blackrock holds 0% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM) for 1,269 shares. Wells Fargo Mn last reported 0% of its portfolio in the stock. Bluestein R H And has invested 0.01% of its portfolio in Tandem Diabetes Care Inc (NASDAQ:TNDM). Northern Trust, a Illinois-based fund reported 222,010 shares. The California-based California State Teachers Retirement Systems has invested 0% in Tandem Diabetes Care Inc (NASDAQ:TNDM). Dafna Mgmt Limited holds 1.87% or 312,756 shares in its portfolio. Geode Capital Management Limited Liability Company holds 0% or 143,685 shares in its portfolio. Ghost Tree Cap Ltd Com has 150,000 shares for 0.33% of their US portfolio. Tpg Group Inc (Sbs) Inc accumulated 0.21% or 2.50 million shares. Millennium Ltd Liability last reported 886,996 shares in the company. Motley Fool Asset Management Ltd holds 390,000 shares or 0.64% of its portfolio. Iguana Healthcare Mgmt Lc holds 175,000 shares or 0.54% of its portfolio.
Insider Transactions: Since May 2, 2016, the stock had 0 insider purchases, and 1 insider sale for $21,213 net activity. $21,213 worth of Tandem Diabetes Care Inc (NASDAQ:TNDM) was sold by Sheridan John F.
More notable recent Tandem Diabetes Care Inc (NASDAQ:TNDM) news were published by: Businesswire.com which released: “Tandem Diabetes Care Now Shipping Next-Generation t:slim X2 Insulin Pump” on October 24, 2016, also Businesswire.com with their article: “Tandem Diabetes Care Schedules Third Quarter 2016 Earnings Press Release and …” published on October 19, 2016, Fool.com published: “Why Insulet Corporation and Tandem Diabetes Care Both Tanked Today” on May 03, 2016. More interesting news about Tandem Diabetes Care Inc (NASDAQ:TNDM) were released by: Prnewswire.com and their article: “Tandem Diabetes Care Announces FDA Approval of t:slim G4 Insulin Pump with CGM …” published on September 09, 2015 as well as Businesswire.com‘s news article titled: “Tandem Diabetes Care Now Taking Orders for Next-Generation t:slim X2 Insulin Pump” with publication date: October 04, 2016.
TNDM Company Profile
Tandem Diabetes Care, Inc., incorporated on January 7, 2008, is a medical device company. The Firm is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Firm makes and sells over three insulin pump products in the United States that are designed to address insulin-dependent diabetes market, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4). The Company’s technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. The Firm also features a software, which is a vivid color touch screen and a micro- universal serial bus (USB) connection that supports both a rechargeable battery and uploads to t:connect Diabetes Management Application (t:connect), its custom cloud data management application that provides display therapy management data from the pump and supported blood glucose meters.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.